Australia's most trusted
source of pharma news
Posted 20 February 2025 AM
After a relatively quiet start to the year in the drug reimbursement landscape, next month could see the tables turn with the number of potential PBS listings surpassing 10 as the next federal election nears.
That figure does not include the five women’s healthcare brands - Besin Healthcare’s menopausal hormone therapies Prometrium, Estrogel, and Estrogel plus Bayer’s contraceptives Yasmin and Yaz - which Health Minister, Mark Butler already announced will be listed from 1 March.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.